Kimberly‑Clark unveiled the operating framework for the entity it will create after absorbing Kenvue, the maker of Tylenol and Listerine. The merged firm will be split into four geographic divisions, with the North American unit slated to generate roughly $18 billion in annual revenue. Core consumer names like Kleenex and Huggies will sit alongside the over‑the‑counter portfolio.

Leadership duties fall to CEO Mike Hsu, who will steer the combined organization from its headquarters. Executives for each regional segment have been named, although the announcement did not disclose individual titles. The move follows months of regulatory clearance work and positions the company to capture synergies across its expanded product mix.

Financial analysts view the four‑segment model as a way to align cost structures and pricing power with distinct market dynamics. Asia‑Pacific Focus Markets, Europe‑Middle East‑Africa, and Enterprise Markets are each projected to deliver $4‑$5 billion in sales, reinforcing a balanced revenue base beyond the dominant North American arm.

By consolidating two of the world’s biggest consumer‑health and personal‑care portfolios, the new entity will command a broader distribution network and stronger bargaining leverage with retailers. The structure sets the stage for immediate integration steps rather than speculative growth forecasts.